• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Adamis up, Mylan down on generic EpiPen approval

June 16, 2017 By Sarah Faulkner

Adamis PharmaceuticalsShares in Adamis Pharmaceuticals (NSDQ:ADMP) soared more than 50% yesterday after it won FDA approval for its generic EpiPen emergency allergy pre-filled syringe, sending shares in competitor Mylan (NSDQ:MYL) down -3%.

For years, Mylan has commanded more than 90% of the market for emergency epinephrine injectors.

Adamis’ device, called Symjepi, is intended to be a cheaper version of Mylan’s EpiPen. Adamis said it plans to set a price for the device before its launch in the 2nd half of 2017 and that the company is looking for a marketing partner.

Mylan has faced criticism and numerous investigations in the past year, after reports revealed that the company has jacked the price of its EpiPen device up nearly 500% since it acquired the auto-injector in 2007. In response to push-back from consumers, Mylan has since launched its own generic for $300.

“We plan to position the product as a lower cost alternative,” Mark Flather, Adamis’ senior director for investor relations & corporate communications for Adamis, said to Reuters. “We want to be part of the solution.”

“With an anticipated lower cost and attractive design, we believe Symjepi will be a meaningful competitor to EpiPen,” Wells Fargo Securities analyst David Maris wrote in a research note.

There are other competitor products available, like Impax Laboratories‘ (NSDQ:IPXL) Adrenaclick device that is sold at CVS for $110 a pair.

Dennis J. Carlo, President and CEO of Adamis, stated, “We are very excited by this approval, and at the same time, are already preparing to submit our 2nd NDA to the FDA.  This 2nd submission is for the junior version of Symjepi.  We are committed to helping patients by providing them with additional therapeutic choices,” president & CEO Dennis Carlo said in prepared remarks. “With an anticipated lower cost, small size and user-friendly design, we believe Symjepi could be an attractive option for a significant portion of both the retail (patient) and non-retail (professional) sectors of the epinephrine market.”

Material from Reuters was used in this report. 

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: adamispharmaceuticals, Impax Laboratories, Mylan

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS